Insider · SEC Form 4 filer
David Young
Past buys: 0 of 3 beat
Companies
Where they file as an insider
Processa Pharmaceuticals (PCSA) Pres. Research & Development, Director Latest filing Jun 30, 2026
Track record
Did their buys beat the typical stock?
Open-market buys10
Quarters checked 6 months later3
Beat the typical stock 0 of 3
Quarters too new to check1
0 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Processa Pharmaceuticals (PCSA) Bought Apr 15–Jun 30, 2026 · $27.8K · 11,180 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Processa Pharmaceuticals (PCSA) Bought Mar 31, 2026 · $4.6K · 1,810 shares Behind typical Mar 31, 2026 $2.52 → Sep 30, 2026 $1.64 · −34.9% (typical stock +1.7%)
Processa Pharmaceuticals (PCSA) Bought Jan 27, 2025 · $99.6K · 124,500 shares Behind typical Mar 31, 2025 $0.37 → Sep 30, 2025 $0.19 · −48.1% (typical stock +7.3%)
Processa Pharmaceuticals (PCSA) Bought Feb 6–7, 2024 · $102K · 41,000 shares Behind typical Mar 31, 2024 $2.36 → Sep 30, 2024 $1.37 · −42.1% (typical stock +3.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.